An extensive head-to-head comparison of CAR T cells with double knockdown of PD-1 and either LAG3, TIM3, or TIGIT in mice bearing NALM6 leukemia showed superior therapeutic efficacy of CAR T cells with simultaneous knockdown of PD-1 and TIGIT [16]. This evidence concerns the gene LAG3 and leukemia.